Large gap with delayed quotes
|
Last quote
06/18/2026
-
02:00:00
|
Bid
06/17/2026 -
21:59:57
|
Bid Volume |
Ask
06/17/2026 -
21:59:57
|
Ask Volume |
|---|---|---|---|---|
|
81.04
+4.49
(
+5.87% )
|
80.99
|
300 |
81.07
|
3,900 |
Analysis date: 16.06.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 01.05.2026.
Interest
Very weak
Very weak
One star since 12.06.2026.
Earnings Rev Trend
-0.10
-0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is negative since 02.06.2026 at a price of 70.82.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 31.03.2026.
4wk Rel Perf
-1.55%
-1.55%
The four-week dividend-adjusted underperformance versus SP500 is 1.55%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 01.05.2026.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -1.49%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.01%.
Mkt Cap in $bn
10.87
10.87
With a market capitalization >$8bn, ARROWHEAD PHARMA is considered a large-cap stock.
G/PE Ratio
-1.09
-1.09
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-24.72
-24.72
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-26.86%
-26.86%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
10
10
Over the last seven weeks, an average of 10 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
159
159
For 1% of index variation, the stock varies on average by 1.59%.
Correlation
0.30
0.30
Stock movements are strongly independent of index variations.
Value at Risk
38.37
38.37
The value at risk is estimated at USD 38.37. The risk is therefore 50.13%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
11.09.2020
11.09.2020